Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 587-601

  Minelli, R ^a   Serpe, L ^a   Pettazzoni, P ^a   Minero, V ^a   Barrera, G ^a   Gigliotti, C L ^b   Mesturini, R ^b   Rosa, A C ^a   Gasco, P ^c   Vivenza, N ^c   Muntoni, E ^a   Fantozzi, R ^a   Dianzani, U ^b   Zara, G P ^a   Dianzani, C ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c NANOVECTOR S R L   (Italy)

Author keywords

adhesion; cholesteryl butyrate; migration; solid lipid nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; CHOLESTERYL BUTYRATE SOLID LIPID NANOPARTICLE; CLAUDIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; COLON CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UMBILICAL VEIN;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHOLESTEROL ESTERS; COLONIC NEOPLASMS; DRUG CARRIERS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NANOPARTICLES;

EID: 84859883485     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01768.x     Document Type: Article

References (65)

1. Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yoshioka T, Okano Y, et al,. (2011). Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells. Eur J Pharmacol 650: 145-150.
2. Barreiro O, Yáñez-Mõ M, Sala-Valdés M, Gutiérrez-Lõpez MD, Ovalle S, Higginbottom A, et al,. (2005). Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation. Blood 105: 2852-2861. (Pubitemid 40446279)
3. Barreiro O, De la Fuente H, Mittelbrunn M, Sánchez-Madrid F, (2007). Functional insights on the polarized redistribution of leukocyte integrins and their ligands during leukocyte migration and immune interactions. Immunol Rev 218: 147-164. (Pubitemid 47052299)
4. Barshishat M, Polak-Charcon S, Schwartz B, (2000). Butyrate regulates E-cadherin transcription, isoform expression and intracellular position in colon cancer cells. Br J Cancer 82: 195-203. (Pubitemid 30008981)
5. Behrens J, (1999). Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 18: 15-30. (Pubitemid 29411089)
6. Boldt S, Weidle UH, Kolch W, (2002). The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831-1838. (Pubitemid 35355933)
7. Brioschi A, Zara GP, Calderoni S, Gasco MR, Mauro A, (2008). Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules 13: 230-254.
8. Buda A, Qualtrough D, Jepson MA, Martines D, Paraskeva C, Pignatelli M, (2003). Butyrate downregulates alpha2beta1 integrin: a possible role in the induction of apoptosis in colorectal cancer cell lines. Gut 52: 729-734. (Pubitemid 36528877)
9. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al,. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
10. Christofori G, Semb H, (1999). The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 24: 73-76. (Pubitemid 29346577)
11. Coussens LM, Fingleton B, Matrisian LM, (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392. (Pubitemid 34270240)
12. Cummings JH, (1981). Short chain fatty acids in the human colon. Gut 22: 763-779. (Pubitemid 12158885)
13. Davis ME, Chen ZG, Shin DM, (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
14. Delzenne N, Cherbut C, Neyrinck A, (2003). Prebiotics: actual and potential effect in inflammatory and malignant colonic disease. Curr Opin Clin Nutr Metab Care 6: 581-586. (Pubitemid 40684580)
15. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, et al,. (2005). Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115: 1765-1776. (Pubitemid 40979715)
16. Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR, et al,. (2006). Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br J Pharmacol 148: 648-656. (Pubitemid 43993055)
17. Dianzani C, Minelli R, Mesturini R, Chiocchetti A, Barrera G, Boscolo S, et al,. (2010). B7h triggering inhibits umbelical vascular endothelial cell adhesiveness to tumor cell lines and polymorphonuclear cells. J Immunol 185: 3970-3979.
18. Dianzani U, Malavasi F, (1995). Lymphocyte adhesion to endothelium. Crit Rev Immunol 15: 167-200.
19. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS, (2004). Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034-1039.
20. Druesne N, Pagniez A, Mayeur C, Thomas N, Cherbuy C, Duée PH, et al,. (2004). Diallyl disulfide (DADS) increases histone acetylation and p21 (waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 25: 1227-1236. (Pubitemid 38968051)
21. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS, (2004). Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5: 254-258. (Pubitemid 38391223)
22. Gasco MR, (2001). Solid lipid nanoparticles for drug delivery. Pharm Technol Eur 13: 32-41.
23. Gasco MR, (2004). Solid lipid nanospheres suitable to a fast internalization into cells. EP 1133286, (24/11/2004)-U.S. 6.685.960 (3/02/2004).
24. Giese A, Bjerkvig R, Berens ME, Westphal M, (2003). Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624-1636. (Pubitemid 46594118)
25. Giovannucci E, Stampfer MJ, Colditz G, Rimm EB, Willett WC, (1992). Relationship of diet to risk of colorectal cancer adenoma in man. J Natl Cancer Inst 84: 91-98.
26. Gonçalves P, Araújo JR, Pinho MJ, Martel F, (2009). Modulation of butyrate transport in Caco-2 cells. Naunyn Schmiedebergs Arch Pharmacol 379: 325-336.
27. Gumbiner BM, (1996). Cell adhesion: the molecul basis of tissue architecture and morphogenesis. Cell 84: 345-357. (Pubitemid 26058560)
28. Gupta N, Martin PM, Prasad PD, Ganapathy V, (2006). SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 78: 2419-2425.
29. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H, (2003). Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 107: 707-714. (Pubitemid 37339723)
30. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ, (2008). Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 15: 104-119. (Pubitemid 350256609)
31. Hayot C, Debeir O, Van Ham P, Van Damme M, Kiss R, Decaestecker C, (2006). Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol 211: 30-40. (Pubitemid 43152095)
32. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al,. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822. (Pubitemid 29080340)
33. Hwang YP, Yun HJ, Kim HG, Han EH, Choi JH, Chung YC, et al,. (2011). Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKCα/ERK1/2-dependent matrix metalloproteinase-9 expression. Toxicol Lett 203: 9-19.
34. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y, (2007). Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6: 2092-2102. (Pubitemid 47052500)
35. Kiely JM, Hu Y, García-Cardeña G, Gimbrone MA, (2003). Lipid raft localization of cell surface E-selectin is required for ligation-induced activation of phospholipase C gamma. J Immunol 171: 3216-3224. (Pubitemid 37093548)
36. Kobayashi H, Tan EM, Fleming SE, (2003). Sodium butyrate inhibits cell growth and stimulates p21WAF1/CIP1 protein in human colonic adenocarcinoma cells independently of p53 status. Nutr Cancer 46: 202-211. (Pubitemid 37500512)
37. Kohno M, Pouyssegur J, (2006). Targeting the ERK signaling pathway in cancer therapy. Ann Med 38: 200-211. (Pubitemid 43675585)
38. Kuno Y, Kondo K, Iwata H, Senga T, Akiyama S, Ito K, et al,. (1998). Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. Jpn J Cancer Res 89: 903-909. (Pubitemid 28486815)
39. Laferrière J, Houle F, Taher MM, Valerie K, Huot J, (2001). Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK2/p38) in the tumor cells. J Biol Chem 276: 33762-33772.
40. Laferrière J, Houle F, Huot J, (2004). Adhesion of HT-29 colon carcinoma cells to endothelial cells requires sequential events involving E-selectin and integrin beta4. Clin Exp Metastasis 21: 257-264.
41. Ley K, Laudanna C, Cybulsky MI, Nourshargh S, (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7: 678-689. (Pubitemid 47327397)
42. Manjunath K, Reddy JS, Venkateswarlu V, (2005). Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 27: 127-144.
43. Matsumura Y, Kataoka K, (2009). Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 100: 572-579.
44. Minucci S, Pelicci PG, (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51. (Pubitemid 43054973)
45. O'Neil BH, Goldberg RM, (2008). Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 13: 1074-1083.
46. Overall CM, Lõpez-Otín C, (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672. (Pubitemid 37328917)
47. Pellizzaro C, Coradini D, Morel S, Ugazio E, Gasco MR, Daidone MG, (1999). Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res 19: 3921-3926.
48. Pullikuth AK, Catling AD, (2010). Extracellular signal-regulated kinase promotes rho-dependent focal adhesion formation by suppressing p190A RhoGAP. Mol Cell Biol 30: 3233-3248.
49. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HMW, Salumbides B, et al,. (2006). Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642. (Pubitemid 43166159)
50. Salomone B, Ponti R, Gasco MR, Ugazio E, Quaglino P, Osella-Abate S, et al,. (2001). In vitro effects of cholesteryl butyrate solid lipd nanospheres as a butyric acid prodrug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin Exp Metastasis 18: 663-673. (Pubitemid 34056323)
51. Sawhney RS, Cookson MM, Omar Y, Hauser J, Brattain MG, (2006). Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem 281: 8497-8510. (Pubitemid 43847952)
52. Sawyer TK, (2004). Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 13: 1-19. (Pubitemid 38111431)
53. Scharlau D, Borowicki A, Habermann N, Hofmann T, Klenow S, Miene C, et al,. (2009). Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res 682: 39-53.
54. Schmalhofer O, Brabletz S, Brabletz T, (2009). E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166.
55. Sebolt-Leopold JS, Herrera R, (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947. (Pubitemid 39626217)
56. Serpe L, Laurora S, Pizzimenti S, Ugazio E, Ponti R, Canaparo R, et al,. (2004). Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs 15: 525-536. (Pubitemid 38736952)
57. Serpe L, Canaparo R, Daperno M, Sostegni R, Martinasso G, Muntoni E, et al,. (2010). Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur J Pharm Sci 39: 428-436.
58. Tremblay PL, Auger FA, Huot J, (2006). Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP kinases. Oncogene 25: 6563-6573. (Pubitemid 44646184)
59. Van Slambrouck S, Jenkins AR, Romero AE, Steelant WF, (2009). Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. Int J Oncol 34: 1717-1726.
60. Weiss L, (1990). Metastatic inefficiency. Adv Cancer Res 54: 159-211. (Pubitemid 20088338)
61. Westesen K, Bunjes H, Kock HJ, (1997). Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 48: 223-236. (Pubitemid 27401980)
62. Wollowski I, Reckemmer G, Pool-Zobel BL, (2001). Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 73: 451S-455S. (Pubitemid 32114158)
63. Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, Wada J, et al,. (2009). Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res 29: 261-270.
64. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC, (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83: 761-769. (Pubitemid 351556021)
65. Zucker S, Cao J, Chen WT, (2000). Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19: 6642-6650. (Pubitemid 32197703)